Ramucirumab plus paclitaxel as switch maintenance in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer: a cost-effectiveness analysis
Ramucirumab plus paclitaxel is unlikely to be cost-effective compared to continuing oxaliplatin-based chemotherapy for patients with advanced HER2-negative GC or GEJC in China and US.
Authors
- Jiyong Liu (ORCID: https://orcid.org/0000-0003-0444-957X)
- Zhengxiong Li (ORCID: https://orcid.org/0009-0000-6031-4755)
- Qiong Du (ORCID: https://orcid.org/0000-0003-4830-9704)
- Jiefeng Luo
Institutions
- Shanghai Medical College of Fudan University (CN)
- Xuzhou Medical College (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-12
- DOI
- https://doi.org/10.3389/fphar.2025.1616826
- Citations
- 2
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.04